A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

NCT00293813 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

247

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG: Alendronate
DRUG: Denosumab
DRUG: Placebo

Sponsor

Amgen